Müllerová, MonikaMaciel, DinaNunes, NádiaWrobel, DominikaStofik, MarcelČervenková Št́astná, LucieKrupková, AlenaCuřínová, PetraNováková, KateřinaBožík, MatějMalý, MarekMalý, JanRodrigues, JoãoStrašák, Tomáš2022-03-082022-12-312021Mullerova, M., Maciel, D., Nunes, N., Wrobel, D., Stofik, M., Červenková Št́astná, L., ... & Strašák, T. (2021). Carbosilane Glycodendrimers for Anticancer Drug Delivery: Synthetic Route, Characterization, and Biological Effect of Glycodendrimer–Doxorubicin Complexes. Biomacromolecules.http://hdl.handle.net/10400.13/4126The complexity of drug delivery mechanisms calls for the development of new transport system designs. Here, we report a robust synthetic procedure toward stable glycodendrimer (glyco-DDM) series bearing glucose, galactose, and oligo(ethylene glycol)-modified galactose peripheral units. In vitro cytotoxicity assays showed exceptional biocompatibility of the glyco-DDMs. To demonstrate applicability in drug delivery, the anticancer agent doxorubicin (DOX) was encapsulated in the glyco-DDM structure. The anticancer activity of the resulting glyco-DDM/DOX complexes was evaluated on the noncancerous (BJ) and cancerous (MCF-7 and A2780) cell lines, revealing their promising generation- and concentration-dependent effect. The glyco DDM/DOX complexes show gradual and pH-dependent DOX release profiles. Fluorescence spectra elucidated the encapsulation process. Confocal fluorescence microscopy demonstrated preferential cancer cell internalization of the glyco-DDM/DOX complexes. The conclusions were supported by computer modeling. Overall, our results are consistent with the assumption that novel glyco DDMs and their drug complexes are very promising in drug delivery and related applications.engCarbosilane glycodendrimersAnticancer drug deliveryGlycodendrimerDoxorubicin complexes.Faculdade de Ciências Exatas e da EngenhariaCentro de Química da Madeirajournal article10.1021/acs.biomac.1c01264